At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 291 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder
In Brief
A Phase 4 clinical trial evaluating Duloxetine and Placebo for Generalized Anxiety Disorder. Completed, enrolled 291 participants across 25 sites in 9 countries.
Detailed Summary
The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesArgentina, Austria, Canada, Germany, Mexico, Poland, Puerto Rico, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartOct 2010
Primary CompletionJul 2012
TodayJul 2026
First PostedMay 7, 2010
Enrollment StartOct 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.2 years ago
Interventions
Duloxetinedrug
Administered by mouth, daily for 10 weeks
Placebodrug
Administered by mouth, daily for 10 weeks